Anixa Biosciences (NASDAQ:ANIX) Receives Buy Rating from D. Boral Capital

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

D. Boral Capital reissued their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX - Free Report) in a research note issued to investors on Tuesday morning,Benzinga reports. The firm currently has a $10.00 price objective on the stock.

Separately, Wall Street Zen raised shares of Anixa Biosciences from a "sell" rating to a "hold" rating in a research note on Friday, June 6th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $9.00.

Anixa Biosciences Stock Up 3.7%

NASDAQ ANIX traded up $0.11 on Tuesday, hitting $3.06. The stock had a trading volume of 57,081 shares, compared to its average volume of 83,358. Anixa Biosciences has a one year low of $2.07 and a one year high of $4.20. The stock has a market cap of $98.56 million, a price-to-earnings ratio of -8.05 and a beta of 0.43. The company's 50-day moving average is $3.22 and its two-hundred day moving average is $2.98.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last posted its earnings results on Tuesday, June 3rd. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. On average, sell-side analysts anticipate that Anixa Biosciences will post -0.41 earnings per share for the current year.

Insider Activity at Anixa Biosciences

In other news, CEO Amit Kumar purchased 10,000 shares of Anixa Biosciences stock in a transaction that occurred on Wednesday, June 4th. The stock was acquired at an average price of $2.85 per share, for a total transaction of $28,500.00. Following the transaction, the chief executive officer owned 569,925 shares in the company, valued at $1,624,286.25. The trade was a 1.79% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Lewis H. Titterton, Jr. purchased 10,000 shares of Anixa Biosciences stock in a transaction that occurred on Thursday, July 31st. The stock was purchased at an average price of $3.08 per share, with a total value of $30,800.00. Following the transaction, the director owned 953,334 shares in the company, valued at $2,936,268.72. This represents a 1.06% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 45,000 shares of company stock valued at $139,200. 25.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Focus Partners Wealth acquired a new position in shares of Anixa Biosciences during the 4th quarter worth $162,000. Jane Street Group LLC acquired a new position in shares of Anixa Biosciences during the 4th quarter worth $67,000. Private Advisor Group LLC acquired a new position in shares of Anixa Biosciences during the 1st quarter worth $35,000. Marshall Wace LLP acquired a new position in shares of Anixa Biosciences during the 2nd quarter worth $39,000. Finally, LPL Financial LLC increased its stake in shares of Anixa Biosciences by 37.2% during the 4th quarter. LPL Financial LLC now owns 42,937 shares of the company's stock worth $100,000 after purchasing an additional 11,633 shares during the last quarter. Institutional investors and hedge funds own 29.13% of the company's stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.